左卡尼汀联合蔗糖铁对血液透析患者肾性贫血及氧化应激的影响被引量：18

Effect of L-carnitine and Iron Sucrose on Renal Anemia and Oxidative Stress in Hemodialysis Patients

导出

摘要目的:探讨左卡尼汀联合蔗糖铁对血透患者肾性贫血及氧化应激的影响。方法:抽选我院2010年3月-2013年5月行维持血透治疗的肾性贫血患者79例,采用数字表法分为对照组(39例)和观察组(40例),对照组采用促红细胞生成素(EPO)、单用蔗糖铁及常规对症治疗,观察组在对照组基础上联用左卡尼汀治疗。比较两组患者治疗前、治疗6个月后血红蛋白(Hb)、血细胞比容(Hct)、血浆铁蛋白(SF)、转铁蛋白饱和度(TSAT)、晚期蛋白质氧化产物(AOPP)及血丙二醛(MDA)水平,并对两组治疗开始时、治疗3、6个月时EPO使用剂量进行比较。结果:治疗6个月后,观察组患者Hb、Hct、SF、TSAT明显高于对照组(P<0.05),AOPP、MDA明显低于对照组(P<0.05);对照组从治疗开始到治疗6个月时一直维持较高的EPO使用剂量,而观察组EPO用量依次递减,至治疗6个月时EPO用量显著低于对照组(P<0.05)。结论:左卡尼汀能联合蔗糖铁治疗肾性贫血的疗效显著,能有效缓解氧化应激反应,降低EPO用量,值得临床推广。 Objective： To explore the impact of L-camitine and iron sucrose on renal anemia and oxidative stress in hemodialysis patients. Methods： 79 cases of patients with renal anemia who treated in our hospital and underwent maintenance hemodialysis treatment from March 2010 to May 2013 were selected, they were randomly divided into control group （39 cases） who used erythropoietin （EPO）, single iron sucrose and conventional symptomatic treatment and observation group （40 cases） who added with L-carnitine treatment on the basis of the control group. Compared the hemoglobin （Hb）, hematocrit （Hct）, plasma ferritin （SF）, transferrin saturation （TSAT）, advanced oxidation protein products （AOPP） and serum malondialdehyde （MDA） level of two groups before treatment and after 6 months treatment, and compared the use of EPO dose at the beginning of treatment and after treatment for 3, 6 months. Results： After 6 months treatment, Hb, Hot, SF, TSAT of observation group were significantly higher than those in control group （P〈0.05）; AOPP, MDA was significantly lower than that of the control group （P〈0.05）. The control group maintained a high dose of EPO from the beginning of treat-ment and after treatment for 6 months, and the treatment group was reduced, it was significantly lower than that of control group after treatment for 6 months （P〈0.05）. Conclusion： L-carnitine combined with iron sucrose in treatment of renal anemia has significantly effect, can effectively alleviate the oxidative stress reaction, reduce the use of EPO dose, which is worthy of clinical application.

作者陈熙军胡开洪鲁毅毛晓琴杨岳

机构地区四川省射洪中医院肾内科四川省南充市中心医院肾内科

出处《现代生物医学进展》 CAS 2015年第15期2907-2909,共3页 Progress in Modern Biomedicine

关键词氧化应激肾性贫血蔗糖铁左卡尼汀 Oxidative stress Renal anemia Iron sucrose L-camitine

分类号 R459.5 [医药卫生—治疗学]

引文网络
相关文献

参考文献20

1Ryndina N, Kravchun P, Tytova G, ct al. Cardiohemodynamic features and character of depressive disorders in patients with anemia varying grades of severity with chronic heart failure and chronic kidney dis- ease[J].Georgian Med News, 2013,23 (218) :40-44.
2刘永泉,岳凌菊.维生素C与促红细胞生成素合用治疗尿毒症肾病贫血的疗效观察[J].辽宁医学院学报,2009,30(5):438-440. 被引量：4
3Malyszko J, Koc-Zorawska E, Malyszko JS, et al. GDF15 is related to anemia and hepcidin in kidney allograft recipients [J]. Nephron Clin Pratt, 2013,123(1):112-117.
4Pfenniger A, Schuller C, Christoph P, et al. Safety and efficacy of high-dose intravenous iron carboxymaltose vs iron sucrose for treat- ment ofpostparturn anemia[J]. J Perinat Med, 2012,40(4):397-402.
5Beguin Y, Jaspers A. Iron sucrose - characteristics, efficacy and regu- latory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas[J]. Expert Opin Pharmacother, 2014,15(14):2087-103.
6Fischer M, Varady J, Hirehe F, et al. Supplementation of L-camitine inpigs: absorption of camitine and effect on plasma and tissue carnitine concentrations[J]. Archives of Animal Nutrition, 2009,63( 1 ):79-80.
7韦小红.左卡尼汀联合重组人促红细胞生成素治疗肾性贫血的疗效观察[J].广西医学,2013,35(9):1218-1219. 被引量：7
8Malaguamera M, Vicari E, Calogero A, et al. Sexual dysfunction in chronic hepatitis C virus patients treated with interferon alpha and ribavirin[J]. J Interferon Cytokine Res, 2008,28(10):603-609.
9Saluk-Juszczak J, Olas B, Wachowicz B, et al. L-camitine modulates blood platelet oxidative stress[J]. Cell Biol Toxicol, 2010,26:355-365.
10Reuter SE, Faull R J, Ranieri E, et al. Endogenous plasma earnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients [J]. Nephrol Dial Transplant, 2009,24 (3): 990-996.